Shareholders' equity · 2011–2025
Neurocrine Biosciences shareholders' equity
$3.3B+25.6% · FY2025
Neurocrine Biosciences (NBIX) reported $3.3B in shareholders' equity for fiscal 2025, +25.6% year on year.
| Fiscal year | Shareholders' equity | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $3.3B | +25.6% | Open → |
| FY20242024-12-31 | $2.6B | +16.0% | Open → |
| FY20232023-12-31 | $2.2B | +30.7% | Open → |
| FY20222022-12-31 | $1.7B | +24.3% | Open → |
| FY20212021-12-31 | $1.4B | +22.0% | Open → |
| FY20202020-12-31 | $1.1B | +76.8% | Open → |
| FY20192019-12-31 | $637M | +32.5% | Open → |
| FY20182018-12-31 | $481M | +29.2% | Open → |
| FY20172017-12-31 | $372M | +18.2% | Open → |
| FY20162016-12-31 | $315M | −25.8% | Open → |
| FY20152015-12-31 | $424M | +103.4% | Open → |
| FY20142014-12-31 | $209M | +73.3% | Open → |
| FY20132013-12-31 | $120M | −22.0% | Open → |
| FY20122012-12-31 | $154M | +156.9% | Open → |
| FY20112011-12-31 | $60.1M | — | Open → |
Shareholders' equity — Shareholders' equity is what remains after subtracting liabilities from assets — the accounting book value of the company, not its market value.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +33.0%
Shareholders' equity at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Neurocrine Biosciences shareholders' equity |url=https://companiesranked.com/en/company/neurocrine-biosciences/shareholders-equity |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Neurocrine Biosciences shareholders' equity. CompaniesRanked. https://companiesranked.com/en/company/neurocrine-biosciences/shareholders-equityBibTeX
@misc{companiesranked-en-company-neurocrine-biosciences-shareholders-equity-2026,
author = {{CompaniesRanked}},
title = {{Neurocrine Biosciences shareholders' equity}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/neurocrine-biosciences/shareholders-equity}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-Q · 0000914475-26-000037 · July 31, 2026
{{cite web |title=Neurocrine Biosciences shareholders' equity — 10-Q (0000914475-26-000037) |url=https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-07-31}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.